On 16 October 2025, Biocon Biologics announced that it is has expanded its collaboration with US-based non-profit pharmaceutical firm Civica, Inc. to supply a new insulin glargine medicine in the United States.
Under the exclusive agreement, Biocon Biologics will manufacture and supply insulin glargine to Civica, and Civica will commercialise the product under Biocon’s existing marketing approval. The product will be promoted and sold under a separate Civica label and trade dress.
On the same day, Governor of California, Gavin Newsom, announced that the State of California will be offering the Civica insulin glargine product under the State-owned CalRx® brand at a maximum cost of $11 per pen.
Biocon’s Semglee® was the first biosimilar approved in the Unites States as interchangeable to Sanofi’s Lantus® (insulin glargine) (July 2021). Eli Lilly’s insulin glargine biosimilar, Rezvoglar®, was US-approved in December 2021. In July 2025, Biocon announced that the FDA approved Kirsty™ (insulin aspart-xjhz) as the first and only interchangeable biosimilar to Novo Nordisk’s NovoLog®.